- Conditions
- ADHD
- Interventions
- Methylphenidate Hydrochloride ER, Behavioral classroom, Placebo, General Classroom, Academic Accommodations
- Drug · Behavioral
- Lead sponsor
- Florida International University
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Miami, Florida • Amherst, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- Short Acting Methylphenidate, Long Acting Methylphenidate
- Drug
- Lead sponsor
- BRC Operations Pty. Ltd.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 1,344 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2019
- U.S. locations
- 5
- States / cities
- Colton, California • Tarzana, California • Englewood Cliffs, New Jersey + 2 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Dexmethylphenidate, Mixed Amphetamine Salts, ER, placebo
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Northbrook, Illinois
- Conditions
- ADHD, Growth
- Interventions
- behavior therapy, Extended release (ER) methylphenidate product, monitoring, drug holiday, caloric supplement
- Behavioral · Drug · Other + 1 more
- Lead sponsor
- Florida International University
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Methylphenidate HCl ER Capsules, 10 mg, Methylphenidate HCl ER Capsules, 15 mg, Methylphenidate HCl ER Capsules, 20 mg
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- South Miami, Florida • Durham, North Carolina
- Conditions
- ADHD, Autism Spectrum Disorder
- Interventions
- Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
- Drug
- Lead sponsor
- Daniel Coury
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 10
- States / cities
- Irvine, California • Los Angeles, California • Portland, Maine + 7 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Methylphenidate HCl ER tablets 1, Placebo, Methylphenidate HCl ER tablets 2, Methylphenidate HCl ER for suspension
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Las Vegas, Nevada
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Guanfacine (GUA), Methylphenidate (MPH)
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 3 Years to 5 Years
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Boston, Massachusetts • Kansas City, Missouri + 2 more
- Conditions
- Attention Deficit Hyperactivity Disorder, ADHD
- Interventions
- Methylphenidate Hydrochloride Extended Release Capsule, Placebo
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Mental Disorders Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorders
- Interventions
- Methylphenidate ER, Cyproheptadine
- Drug
- Lead sponsor
- Douglas Sears
- Individual
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Van Nuys, California
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules
- Drug
- Lead sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Other
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 13
- States / cities
- Dothan, Alabama • Anaheim, California • Jacksonville, Florida + 10 more
- Conditions
- Attention Deficit Hyperactivity Disorder, ADHD
- Interventions
- Methylphenidate Hydrochloride Extended Release Capsules, Placebo
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • Irvine, California • National City, California + 13 more
- Conditions
- Hoarding Disorder
- Interventions
- Methylphenidate ER
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Hartford, Connecticut • New York, New York
- Conditions
- Attention-deficit/Hyperactivity Disorder
- Interventions
- Methylphenidate Hydrochloride Extended Release Capsule
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
- Drug
- Lead sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Newport Beach, California • Bradenton, Florida • Maitland, Florida + 4 more
- Conditions
- Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
- Interventions
- Methylphenidate extended-release liquid formulation
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts